These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 25205713)

  • 41. [Iron deficiency anaemia due to a matriptase-2 mutation].
    Cuijpers ML; Wiegerinck ET; Brouwer R; de Witte TJ; Swinkels DW
    Ned Tijdschr Geneeskd; 2010; 154():A1038. PubMed ID: 20719010
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Erythroferrone and matriptase-2 independently regulate hepcidin expression.
    Aschemeyer S; Gabayan V; Ganz T; Nemeth E; Kautz L
    Am J Hematol; 2017 May; 92(5):E61-E63. PubMed ID: 28187515
    [No Abstract]   [Full Text] [Related]  

  • 43. The type II transmembrane serine protease, matriptase-2: Possible links to cancer?
    Sanders AJ; Webb SL; Parr C; Mason MD; Jiang WG
    Anticancer Agents Med Chem; 2010 Jan; 10(1):64-9. PubMed ID: 20015002
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Membrane-type serine protease-1/matriptase induces interleukin-6 and -8 in endothelial cells by activation of protease-activated receptor-2: potential implications in atherosclerosis.
    Seitz I; Hess S; Schulz H; Eckl R; Busch G; Montens HP; Brandl R; Seidl S; Schömig A; Ott I
    Arterioscler Thromb Vasc Biol; 2007 Apr; 27(4):769-75. PubMed ID: 17255532
    [TBL] [Abstract][Full Text] [Related]  

  • 45. En Route to New Therapeutic Options for Iron Overload Diseases: Matriptase-2 as a Target for Kunitz-Type Inhibitors.
    Beckmann AM; Maurer E; Lülsdorff V; Wilms A; Furtmann N; Bajorath J; Gütschow M; Stirnberg M
    Chembiochem; 2016 Apr; 17(7):595-604. PubMed ID: 26762582
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Strong expression association between matriptase and its substrate prostasin in breast cancer.
    Bergum C; Zoratti G; Boerner J; List K
    J Cell Physiol; 2012 Apr; 227(4):1604-9. PubMed ID: 21678412
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Modulating the selectivity of matriptase-2 inhibitors with unnatural amino acids.
    St-Georges C; Désilets A; Béliveau F; Ghinet M; Dion SP; Colombo É; Boudreault PL; Najmanovich RJ; Leduc R; Marsault É
    Eur J Med Chem; 2017 Mar; 129():110-123. PubMed ID: 28219045
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Substrate specificity of human matriptase-2.
    Wysocka M; Gruba N; Miecznikowska A; Popow-Stellmaszyk J; Gütschow M; Stirnberg M; Furtmann N; Bajorath J; Lesner A; Rolka K
    Biochimie; 2014 Feb; 97():121-7. PubMed ID: 24161741
    [TBL] [Abstract][Full Text] [Related]  

  • 49. From prediction to experimental validation: desmoglein 2 is a functionally relevant substrate of matriptase in epithelial cells and their reciprocal relationship is important for cell adhesion.
    Wadhawan V; Kolhe YA; Sangith N; Gautam AK; Venkatraman P
    Biochem J; 2012 Oct; 447(1):61-70. PubMed ID: 22783993
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The Impact of Acute Matriptase Inhibition in Hepatic Inflammatory Models.
    Pomothy J; Szombath G; Rokonál P; Mátis G; Neogrády Z; Steinmetzer T; Pászti-Gere E
    Biomed Res Int; 2016; 2016():6306984. PubMed ID: 27642598
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Iron refractory iron deficiency anemia.
    De Falco L; Sanchez M; Silvestri L; Kannengiesser C; Muckenthaler MU; Iolascon A; Gouya L; Camaschella C; Beaumont C
    Haematologica; 2013 Jun; 98(6):845-53. PubMed ID: 23729726
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Role of the stem domain of matriptase in the interaction with its physiological inhibitor, hepatocyte growth factor activator inhibitor type I.
    Kojima K; Tsuzuki S; Fushiki T; Inouye K
    J Biochem; 2009 Jun; 145(6):783-90. PubMed ID: 19276202
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Inhibition of human matriptase by eglin c variants.
    Désilets A; Longpré JM; Beaulieu ME; Leduc R
    FEBS Lett; 2006 Apr; 580(9):2227-32. PubMed ID: 16566926
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Identification of the first low-molecular-weight inhibitors of matriptase-2.
    Sisay MT; Steinmetzer T; Stirnberg M; Maurer E; Hammami M; Bajorath J; Gütschow M
    J Med Chem; 2010 Aug; 53(15):5523-35. PubMed ID: 20684597
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Neogenin interacts with matriptase-2 to facilitate hemojuvelin cleavage.
    Enns CA; Ahmed R; Zhang AS
    J Biol Chem; 2012 Oct; 287(42):35104-35117. PubMed ID: 22893705
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The role of Matriptase-2 during the early postnatal development in humans.
    De Falco L; Bruno M; Yilmaz-Keskin E; Sal E; Büyükavci M; Kaya Z; Girelli D; Iolascon A
    Haematologica; 2016 Apr; 101(4):e126-8. PubMed ID: 26802052
    [No Abstract]   [Full Text] [Related]  

  • 57. The role of type II transmembrane serine protease-mediated signaling in cancer.
    Tanabe LM; List K
    FEBS J; 2017 May; 284(10):1421-1436. PubMed ID: 27870503
    [TBL] [Abstract][Full Text] [Related]  

  • 58. N-glycosylation is required for matriptase-2 autoactivation and ectodomain shedding.
    Jiang J; Yang J; Feng P; Zuo B; Dong N; Wu Q; He Y
    J Biol Chem; 2014 Jul; 289(28):19500-7. PubMed ID: 24867957
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Matriptase-2 regulates iron homeostasis primarily by setting the basal levels of hepatic hepcidin expression through a nonproteolytic mechanism.
    Enns CA; Weiskopf T; Zhang RH; Wu J; Jue S; Kawaguchi M; Kataoka H; Zhang AS
    J Biol Chem; 2023 Oct; 299(10):105238. PubMed ID: 37690687
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The type II transmembrane serine protease matriptase-2--identification, structural features, enzymology, expression pattern and potential roles.
    Ramsay AJ; Reid JC; Velasco G; Quigley JP; Hooper JD
    Front Biosci; 2008 Jan; 13():569-79. PubMed ID: 17981570
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.